vs
Side-by-side financial comparison of Organon & Co. (OGN) and Welltower (WELL). Click either name above to swap in a different company.
Welltower is the larger business by last-quarter revenue ($2.8B vs $1.5B, roughly 1.9× Organon & Co.). Welltower runs the higher net margin — 51.6% vs 10.0%, a 41.6% gap on every dollar of revenue. On growth, Welltower posted the faster year-over-year revenue change (180.6% vs -3.5%). Over the past eight quarters, Welltower's revenue compounded faster (42.4% CAGR vs -4.7%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure. As of December 31, 2022, the company had investments in approximately 3,000 properties, all of which were in the United States, Canada, and the United Kingdom.
OGN vs WELL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.8B |
| Net Profit | $146.0M | $1.5B |
| Gross Margin | 53.6% | — |
| Operating Margin | — | — |
| Net Margin | 10.0% | 51.6% |
| Revenue YoY | -3.5% | 180.6% |
| Net Profit YoY | 67.8% | 93.7% |
| EPS (diluted) | $0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | $2.8B | ||
| Q4 25 | $1.5B | $2.6B | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.5B | $1.9B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.4B |
| Q1 26 | $146.0M | $1.5B | ||
| Q4 25 | $-205.0M | $117.8M | ||
| Q3 25 | $160.0M | $282.2M | ||
| Q2 25 | $145.0M | $304.6M | ||
| Q1 25 | $87.0M | $257.3M | ||
| Q4 24 | $109.0M | $123.8M | ||
| Q3 24 | $359.0M | $456.8M | ||
| Q2 24 | $195.0M | $260.7M |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | 24.3% | ||
| Q3 25 | 53.5% | 23.5% | ||
| Q2 25 | 54.8% | 23.2% | ||
| Q1 25 | 55.6% | 21.6% | ||
| Q4 24 | 56.3% | 20.0% | ||
| Q3 24 | 58.3% | 19.8% | ||
| Q2 24 | 58.4% | 20.2% |
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | — | ||
| Q3 25 | 15.2% | 14.2% | ||
| Q2 25 | 14.4% | 15.1% | ||
| Q1 25 | 6.7% | 10.7% | ||
| Q4 24 | 8.1% | 6.2% | ||
| Q3 24 | 13.1% | 12.2% | ||
| Q2 24 | 14.6% | 6.5% |
| Q1 26 | 10.0% | 51.6% | ||
| Q4 25 | -13.6% | 4.6% | ||
| Q3 25 | 10.0% | 13.7% | ||
| Q2 25 | 9.1% | 15.5% | ||
| Q1 25 | 5.8% | 13.8% | ||
| Q4 24 | 6.8% | 7.0% | ||
| Q3 24 | 22.7% | 30.2% | ||
| Q2 24 | 12.1% | 18.7% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $-0.78 | $0.13 | ||
| Q3 25 | $0.61 | $0.41 | ||
| Q2 25 | $0.56 | $0.45 | ||
| Q1 25 | $0.33 | $0.40 | ||
| Q4 24 | $0.42 | $0.20 | ||
| Q3 24 | $1.38 | $0.73 | ||
| Q2 24 | $0.75 | $0.42 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
WELL
| Resident fees and services | $1.9B | 67% |
| Other | $822.6M | 29% |
| Rental income | $103.4M | 4% |
